CRSP
CRISPR Therapeutics AG · Healthcare · Biotechnology
Momentum inputs (comparable managers): holder breadth 0.0% · share flow +3.7% · net new positions -6.7% · formula
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 2 | 0 | 22.66K | $1.16M | n/a | −1 |
| Q2 2026 | 114 | +6 | 51.82M | $2.83B | +10 | −5 |
| Q1 2026 | 112 | -2 | 52.07M | $2.48B | +5 | −8 |
| Q4 2025 | 114 | 0 | 52.74M | $2.77B | +1 | n/a |
| Q3 2025 | 15 | 0 | 31.49M | $2.04B | +1 | −2 |
| Q2 2025 | 13 | 0 | 27.95M | $1.36B | +1 | −1 |
| Q1 2025 | 10 | +2 | 16.56M | $563.38M | +2 | n/a |
| Q4 2024 | 8 | -2 | 14.13M | $556.07M | n/a | −2 |
| Q3 2024 | 9 | -1 | 10.14M | $476.58M | n/a | −1 |
| Q2 2024 | 10 | n/a | 10.63M | $574.07M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | ARK Investment Management ✦ | 9.79M | -3.9% | $634.29M | 3.8% | ▼ Trim | 6 | SEC ↗ |
| 2 | BlackRock ✦ (passive) | 7.05M | +16.2% | $456.92M | 0.0% | ▲ Add | 2 | SEC ↗ ×15 |
| 3 | State Street Global Advisors ✦ (passive) | 4.01M | +22.5% | $259.71M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 4 | The Vanguard Group ✦ (passive) | 2.36M | +2.9% | $153.25M | 0.0% | ▲ Add | 2 | SEC ↗ ×6 |
| 5 | Geode Capital Management ✦ (passive) | 2.14M | +3.3% | $138.79M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 6 | Fidelity (FMR) ✦ | 1.89M | -2.2% | $122.21M | 0.0% | ▼ Trim | 2 | SEC ↗ ×3 |
| 7 | Morgan Stanley ✦ | 1.40M | n/a | $90.60M | 0.0% | n/c | 1 | SEC ↗ ×8 |
| 8 | JPMorgan Chase ✦ | 1.19M | n/a | $76.92M | 0.0% | n/c | 1 | SEC ↗ ×16 |
| 9 | Two Sigma Investments ✦ | 1.04M | -32.4% | $67.71M | 0.1% | ▼ Trim | 6 | SEC ↗ |
| 10 | Goldman Sachs Group ✦ | 233.54K | n/a | $15.14M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 11 | Citadel Advisors ✦ | 167.10K | +785.2% | $10.83M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 12 | Millennium Management ✦ | 86.28K | +23.1% | $5.59M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 13 | T. Rowe Price ✦ | 76.53K | +15.3% | $4.96M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 14 | Wellington Management ✦ | 36.49K | New | $2.36M | 0.0% | New | 1 | SEC ↗ ×4 |
| 15 | AQR Capital Management ✦ | 28.37K | +31.3% | $1.84M | 0.0% | ▲ Add | 3 | SEC ↗ ×4 |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Wellington Management | $2.36M | 0.0% |
Exited
| Norges Bank | $19.77M | was 0.0% |
| Gotham Asset Management | $248,113 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 488 holders, 76.60M shares, $3.47B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer, Director · 47.84K sh · $2.38M
Director · 14.51K sh · $720,373
Officer, Director · 4.10K sh · $201,867
Officer · 1.04K sh · $51,230
Officer · 1.99K sh · $119,481
Officer · 10.40K sh · $626,460
Director · 13.68K sh · $780,935
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology